01
Tumor context
TenSixty evaluates disease-state epitopes that may be accessible to selected antibodies.
Epitope-defined therapeutics
Expanding the druggable oncology universe.
TenSixty studies tumor-selective epitopes that can be difficult to resolve with protein-level approaches—and translates those insights into oncology therapeutics.
A different level of resolution
Therapeutic opportunity is shaped at the epitope level.
The same protein can present very different binding opportunities in tumor and healthy tissue. Cellular state and proteoform context can influence what an antibody is able to see.
02
Healthy context
The corresponding epitope may remain masked in healthy cellular context.
Our platform
From native tumor biology to differentiated therapeutic leads.
01 / Measure
GlycoLens
Resolves disease-state proteoforms and surfaces candidate tumor-selective epitopes from matched biological context.
02 / Prioritize
Atlas xTI
Places each opportunity in tumor, healthy-tissue, indication, and modality context to guide the right therapeutic strategy.
03 / Build
Therapeutic discovery
Preserves native biology, screens for real tumor selectivity, and links each binder to its antigen, epitope, sequence, and function.
Pipeline
A growing portfolio of epitope-defined programs.
Our platform is built to generate differentiated oncology assets across targets, indications, and therapeutic modalities.
Explore the portfolioOur vision
Better targets can unlock better medicines for people with cancer.
By connecting experimental biology with computational learning, we aim to turn overlooked cell-surface differences into new therapeutic possibilities.
Built across disciplines
One team, fluent in biology, data, and drug discovery.
We bring together expertise in multi-omics platforms, machine learning, antibody discovery, and therapeutic development around one shared objective: meaningful impact for patients.
Our investors
Supported by partners who believe in our mission.
Connect with TenSixty